Lonza AG
Location
WALLIS
Founded
1897-12-07
Website
Risk Signals
2690 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Industrial Organic Chemicals, Not Elsewhere Classified), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Lonza AG
Live alerts from global media, monitored by Business Radar
2025-02-04 (transkript.de)
An overview of January
The shortened month of January brought a lot of movement in our news ticker. Here is the overview of the headlines of our short reports at the beginning of 2025.
Read more
2025-02-04 (transkript.de)
An overview of January
The shortened month of January brought a lot of movement in our news ticker. Here is the overview of the headlines of our short reports at the beginning of 2025.
Read more
2025-01-31 (seacoastonline.com)
Eversource, Unitil and Lonza partner to slash energy use and emissions
Lonza signs new multi-year agreements with utility companies to lower energy use at its Portsmouth site.
Read more
2025-01-31 (seacoastonline.com)
Eversource, Unitil and Lonza partner to slash energy use and emissions
Lonza signs new multi-year agreements with utility companies to lower energy use at its Portsmouth site.
Read more
2025-01-31 (seacoastonline.com)
Eversource, Unitil and Lonza partner to slash energy use and emissions
Lonza signs new multi-year agreements with utility companies to lower energy use at its Portsmouth site.
Read more
2025-01-31 (seacoastonline.com)
Eversource, Unitil and Lonza partner to slash energy use and emissions
Lonza signs new multi-year agreements with utility companies to lower energy use at its Portsmouth site.
Read more
2025-01-18 (geneonline.com)
Neuro, Pain, and Cancer Top the List at JPM 2025 Healthcare Conference -
The 2025 J.P. Morgan Healthcare Conference highlights innovations in neurodegenerative diseases, cancer, and pain management.
Read more
2025-01-18 (geneonline.com)
Neuro, Pain, and Cancer Top the List at JPM 2025 Healthcare Conference -
The 2025 J.P. Morgan Healthcare Conference highlights innovations in neurodegenerative diseases, cancer, and pain management.
Read more
2025-01-17 (ipo.se)
BioStock: Iconovo and Lonza start collaboration to strengthen obesity project -
Iconovo entered into a strategic collaboration with Lonza to take the next step in the company's obesity project. By contributing its expertise in spray-dried powder formulations, Lonza will play a central role in the development of a reformulated, intranasal drug treatment for obesity.
Read more
2025-01-17 (ipo.se)
BioStock: Iconovo and Lonza start collaboration to strengthen obesity project -
Iconovo entered into a strategic collaboration with Lonza to take the next step in the company's obesity project. By contributing its expertise in spray-dried powder formulations, Lonza will play a central role in the development of a reformulated, intranasal drug treatment for obesity.
Read more
2025-01-17 (ipo.se)
BioStock: Iconovo and Lonza start collaboration to strengthen obesity project -
Iconovo entered into a strategic collaboration with Lonza to take the next step in the company's obesity project. By contributing its expertise in spray-dried powder formulations, Lonza will play a central role in the development of a reformulated, intranasal drug treatment for obesity.
Read more
2025-01-16 (globenewswire.com)
Global Exosome Diagnostics Market is Projected to Boom with an Enormous CAGR of ~47% by 2032 | DelveInsight
The rising incidence of cancer is boosting the demand for advanced diagnostic tools, such as exosome-based diagnostics, which provide non-invasive and...
Read more